Randomized Dose‐Ranging Study of the Safety and Efficacy of WR 238605 (Tafenoquine) in the Prevention of Relapse ofPlasmodium vivaxMalaria in Thailand | Zendy

Douglas S. Walsh | Zendy; S Looareesuwan | Zendy; Polrat Wilairatana | Zendy; D. Gray Heppner | Zendy; Douglas B. Tang | Zendy; Thomas G. Brewer | Zendy; Watcharee Chokejindachai | Zendy; Parnpen Viriyavejakul | Zendy; Dennis E. Kyle | Zendy; Wilbur K. Milhous | Zendy; Brian G. Schuster | Zendy; John Horton | Zendy; David J. Braitman | Zendy; Ralf P. Brueckner | Zendy

Open Access

Randomized Dose‐Ranging Study of the Safety and Efficacy of WR 238605 (Tafenoquine) in the Prevention of Relapse ofPlasmodium vivaxMalaria in Thailand

Author(s) -

Douglas S. Walsh,

S Looareesuwan,

Polrat Wilairatana,

D. Gray Heppner,

Douglas B. Tang,

Thomas G. Brewer,

Watcharee Chokejindachai,

Parnpen Viriyavejakul,

Dennis E. Kyle,

Wilbur K. Milhous,

Brian G. Schuster,

John Horton,

David J. Braitman,

Ralf P. Brueckner

Publication year - 1999

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/315034

Subject(s) - plasmodium vivax , chloroquine , malaria , medicine , group b , dose ranging study , randomized controlled trial , gastroenterology , vivax malaria , relapse prevention , group a , surgery , plasmodium falciparum , double blind , immunology , pathology , clinical psychology , alternative medicine , placebo

WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n=15) received 300 mg daily for 7 days; group B (n=11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n=9), 1 dose of 500 mg. A fourth group (D; n=9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n=23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research